Vandetanib (ZD6474)

Catalog No.S1046

Vandetanib (ZD6474) Chemical Structure

Molecular Weight(MW): 475.35

Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay. It also inhibits VEGFR3 and EGFR with IC50 of 110 nM and 500 nM, respectively. Not sensitive to PDGFRβ, Flt1, Tie-2 and FGFR1 with IC50 of 1.1-3.6 μM. No activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R with IC50 above 10 μM.

Size Price Stock Quantity  
USD 147 In stock
USD 470 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

7 Customer Reviews

  • (A) Representative in vivo bioluminescence of mice at and during time of treatment. Derived cell lines with either BCR-ABL1 WT or V299L was tail-vein injected into immunocompetent recipient mice. Initial imaging was performed at day 10 post-transplantation. Mice were subsequently treated once daily with vehicle, 10 mg/kg dasatinib, 50 mg/kg imatinib, 50 mg/kg vandetanib, or 50 mg/kg foretinib.
    (B) Fold change in total whole-mouse bioluminescence signal between post- and pre-treatment. Mice bearing BCR-ABL1 V299L ALLs showed significant tumor burden reduction upon treatment with foretinib or vandetanib. Statistical significance determined by Mann-Whitney test. *p < 0.05, **p < 0.01.

    Cell, 2016, 165(1):234-46.. Vandetanib (ZD6474) purchased from Selleck.

    Vandetanib reduced extracellular nitrite levels in endothelial cells. MS1 endothelial cells (ECs) were incubated with 1 mol/L of vandetanib or matched vehicle (dimethyl sulfoxide [DMSO]), 50 ng/mL of vascular endothelial growth factor (VEGF) or matched vehicle (PBS; 0.5 hours), and L-arginine and soluble N-ethylmaleamide sensitive factor attachment protein (SNAP) added (1.5 hours). Vandetanib lowered nitrite levels in MS1 Ecs (*P0.0003). VEGF was used a positive control and increased nitrite levels (**P0.02). These findings indicate that vandetanib lowered endothelial cell NO levels.

    Hypertension 2011 58, 85-92. Vandetanib (ZD6474) purchased from Selleck.

  • Vandetanib reduced phosphorylation of Akt in endothelial cells (ECs). MS1 ECs were incubated with 1 μmol/L of vandetanib or matched vehicle (dimethyl sulfoxide [DMSO]; 1 hour). Western blotting analysis showed that vandetanib decreased phosphorylation of Akt (S473) in MS1 ECs (*P<0.01; n=6 per group, studies done in triplicate). These findings show that vandetanib reduced Akt activity.

    Hypertension 2011 58, 85-92. Vandetanib (ZD6474) purchased from Selleck.

    Vandetanib increases membrane localization of endothelial NO synthase (eNOS). MS1 endothelial cells (ECs) were incubated with 1 μmol/L of vandetanib or matched vehicle (dimethyl sulfoxide [DMSO]). Western blotting analysis showed that vandetanib increases membrane localization of eNOS compared with control (*P<0.04; n=4 per group, studies done in triplicate). These findings show that vandetanib increased the membrane localization of eNOS compared with control.

    Hypertension 2011 58, 85-92. Vandetanib (ZD6474) purchased from Selleck.

  • (H) Anti-pSTAT3Y705, total STAT3, pSRCy416 of RWPE-1 transfectants treated for 6 hours with vandetanib at the indicated concentrations. Actin was used as loading control.

    J Cancer, 2017, 8(1):140-145. Vandetanib (ZD6474) purchased from Selleck.

    LS-007 inhibits CDK1/CDK7/CDK9 activity in AL cells. HL-60 (A), CCRF-CEM (B) cells were treated with increasing concentrations of LS-007 or flavopiridol for 2 h, and cell lysates were collected and examined by immunoblotting with the indicated antibodies.

    Acta Pharmacol Sin, 2016, 37(11):1481-1489. Vandetanib (ZD6474) purchased from Selleck.

  • Breast cancer cells were pretreated with 100ng/ml EGF for 15 min and then treated with the indicated concentrations of Vandetanib for 24 hours.

     

     

    Dr. Zhang of Tianjin Medical University. Vandetanib (ZD6474) purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay. It also inhibits VEGFR3 and EGFR with IC50 of 110 nM and 500 nM, respectively. Not sensitive to PDGFRβ, Flt1, Tie-2 and FGFR1 with IC50 of 1.1-3.6 μM. No activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R with IC50 above 10 μM.
Targets
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
EGFR [1]
(Cell-free assay)
40 nM 110 nM 500 nM
In vitro

Vandetanib also inhibits VEGFR3 and EGFR with IC50 of 110 nM and 500 nM, respectively. Vandetanib is not sensitive to PDGFRβ, Flt1, Tie-2 and FGFR1 with IC50 of 1.1-3.6 μM, while almost has no activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R with IC50 above 10 μM. Vandetanib inhibits VEGF-, EGF- and bFGF-stimulated HUVEC proliferation with IC50 of 60 nM, 170 nM and 800 nM, with no effect on basal endothelial cell growth. Vandetanib inhibits tumor cell growth with IC50 of 2.7 μM (A549) to 13.5 μM (Calu-6). [1] Vandetanib displays an inhibitory effect on the basal ABCG2-ATPase. Parental and ABCG2-expressing A431 cells showed similar sensitivities toward Vandetanib. Exposure to EGFR inhibitors decreases pEGFR levels in A431 cells, with Vandetanib displaying only a moderate effect. Vandetanib displays a slight but measurable effect, whereas gefitinib, pelitinib and neratinib completely inhibit ABCG2-mediated efflux of mitoxantrone from A431/ABCG2 cells, similarly to the specific ABCG2 inhibitor Ko143. [2] Vandetanib inhibits both PC3wt and PC3R cell lines with similar IC50 of 13.3 μM and 11.5 μM, respectively. [3] Vandetanib suppresses phosphorylation of VEGFR2 in HUVEC and EGFR in hepatoma cells and inhibits cell proliferation. [4] Vandetanib causes an accumulation of cells in the G0-G1 phases in GEO and OVCAR-3 cells and increases apoptosis in OVCAR-3, ZR-75-1, MCF-10A ras, and GEO cells. Vandetanib causes a dose-dependent inhibition of EGFR phosphorylation in mouse NIH-EGFR fibroblasts and human MCF-10A ras breast cancer cells, two cell lines that overexpress the human EGFR. Vandetanib treatment results in a dose-dependent inhibition of soft agar growth in seven human cell lines (breast, colon, gastric, and ovarian) with functional EGFR but lacking VEGFR2. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SN179  M1[y[mZ2dmO2aX;uJGF{e2G7 MUO1NFDjiImwTdMg NY\HfGFHOTZiaB?= M2jDU4lv[3KnYYPld{BEYEOUNDDlfJBz\XO|aX;uJJNq\26rZnnjZY51dHl? M2XoTlI2Pjd4Nkmx
SN186 MlXtSpVv[3Srb36gRZN{[Xl? NXT0XnFzPTBy4pEJcm3DqA>? MkPDNVYhcA>? NGX5NlNqdmO{ZXHz[ZMhS1iFUkSg[ZhxemW|c3nvckB{cWewaX\pZ4FvfGy7 MlX4NlU3PzZ4OUG=
SN179  NImyR|NHfW6ldHnvckBCe3OjeR?= MnftOVAx6oDLbl5CpC=> NEnVdo4yPiCq NH7XSnlmdmijbnPld{B1cGViQ2jDUFEzKGSrcnXjeIVlKG2rZ4LheIlwdg>? MWmyOVY4PjZ7MR?=
SN179  NFX3RXdHfW6ldHnvckBCe3OjeR?= M4\zbVUxOOLCiX7NxsA> MWCxOkBp NHuwNllqdmO{ZXHz[ZMh[mG|YXygcYloemG2aX;uxsA> MkTpNlU3PzZ4OUG=
Jurkat NFq5VJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[0U|czyqCqwrC= MkfGS2k2OD1zLkWgxtEhOC5{IN88US=> MnzoNlQ3QDF{MEW=
K-562 M4TsPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVT6V4IzPzMEoHlCpC=> MWnHTVUxRTFwODFCtUAxNjFizszN NGfFOmwzPDZ6MUKwOS=>
NCTC-2544 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYO3NuKhcMLi NHLwcVJIUTVyPUSuOkDDuSByLkOg{txO MWGyOFY5OTJyNR?=
A-431 MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfDVXU4OsLiaNMg M{DoeWdKPTB;Mj60JOKyKDBwMzFOwG0> MoXKNlQ3QDF{MEW=
SK-N-SH MlLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVmwMlYzPS1{MDFOwG0> MmO5OFghcA>? Mn3tSG1UVw>? M{DyRolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NYjRUmtpOjR|OUmwO|Q>
SH-SY5Y M1SwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzTdIExNjZ{NT2yNEDPxE1? MkX2OFghcA>? MYHEUXNQ NXLsWmhycW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NF\oO3YzPDN7OUC3OC=>
SK-N-SH MlLERZBweHSxc3nzbUBCe3OjeR?= MWq1M|ExNzJyIN88US=> M2f1blQ5KGh? M3S1XGROW09? NUXvV2FScW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> MnHvNlQ{QTlyN{S=
SH-SY5Y M1j1V2Fxd3C2b4Ppd4khSXO|YYm= MoPWOU8yOC9{MDFOwG0> MXy0PEBp MYPEUXNQ NWDQbpVncW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> MmXkNlQ{QTlyN{S=
SK-N-SH NHTDO2ZHfW6ldHnvckBCe3OjeR?= M3\CeVUwOTBxMkCg{txO NGrHWm81QCCq NX3C[lJKTE2VTx?= NXzBRZA{cW6mdXPld{BIOSCyaHHz[UBk\WyuIHP5Z4xmKGG{cnXzeC=> MYWyOFM6QTB5NB?=
SH-SY5Y MmPCSpVv[3Srb36gRZN{[Xl? MWi1M|ExNzJyIN88US=> NX[2dHZjPDhiaB?= MUPEUXNQ MWLpcoR2[2W|IFexJJBp[XOnIHPlcIwh[3mlbHWgZZJz\XO2 M3fuWFI1Ozl7MEe0
SK-N-SH MkTjSpVv[3Srb36gRZN{[Xl? NEDxcFAyNzVxMUCg{txO M2XMXlQ5KGh? MUnEUXNQ M1zWO4lvcGmkaYTzJHJGXCCyaH;zdIhwenmuYYTpc44> MUiyOFM6QTB5NB?=
SH-SY5Y M4fCWmZ2dmO2aX;uJGF{e2G7 NY\RZ5ZwOS93L{GwJO69VQ>? MoniOFghcA>? NV\u[YNyTE2VTx?= NX70RohlcW6qaXLpeJMhWkWWIIDoc5NxcG:{eXzheIlwdg>? MVKyOFM6QTB5NB?=
SK-N-SH MVLGeY5kfGmxbjDBd5NigQ>? MkXyOU8yOCEQvF2= NUPVVppJPDhiaB?= M2S1VmROW09? NFy0V2RqdmirYnn0d{BpfW2jbjDORkBk\WyuIH3p[5JifGmxbh?= NWLacnk5OjR|OUmwO|Q>
SH-SY5Y M37UUWZ2dmO2aX;uJGF{e2G7 MV61M|ExKM7:TR?= NY[0S5hwPDhiaB?= NUCxV|E6TE2VTx?= NVfxXodzcW6qaXLpeJMhcHWvYX6gUmIh[2WubDDtbYdz[XSrb36= MoTkNlQ{QTlyN{S=
SK-N-SH NHPKOnZHfW6ldHnvckBCe3OjeR?= MUW1M|ExKM7:TR?= NWCxeWdWPDhiaB?= M4jDPWROW09? MoC0bY5pcWKrdIOgbJVu[W5iTlKgZ4VtdCCrbo\hd4lwdg>? M4XKWVI1Ozl7MEe0
SH-SY5Y NX7s[XY4TnWwY4Tpc44hSXO|YYm= M1vE[|UwOTBizszN MVy0PEBp M3nIZWROW09? M4TXTIlvcGmkaYTzJIh2dWGwIF7CJINmdGxiaX72ZZNqd25? MYOyOFM6QTB5NB?=
SK-N-SH NHz1VIhHfW6ldHnvckBCe3OjeR?= NW\we2NUPSEQvF2= MWCyOE81QC95MjDo MYDEUXNQ Mkfkd5VxeHKnc4Pld{B1cGViZYjwdoV{e2mxbjDv[kBEYEOUNDDhcoQhVU2SMUSgcXJPSQ>? NF6yW2QzPDN7OUC3OC=>
SH-SY5Y NYm0fWZRTnWwY4Tpc44hSXO|YYm= MlPYOUDPxE1? NYLte3p4OjRxNEivO|IhcA>? MVPEUXNQ MmXXd5VxeHKnc4Pld{B1cGViZYjwdoV{e2mxbjDv[kBEYEOUNDDhcoQhVU2SMUSgcXJPSQ>? MVWyOFM6QTB5NB?=
SK-N-SH NV\j[3hLTnWwY4Tpc44hSXO|YYm= NUTVb|dOPSEQvF2= MmT0OFgwPzJiaB?= MlToSG1UVw>? NGOySJN{fXCycnXzd4V{KGW6cILld5Nqd25ib3[geIhmKEO[Q2K0JIFv\CCPTWCxOEBxem:2ZXnu MVyyOFM6QTB5NB?=
SH-SY5Y NX\mXYNsTnWwY4Tpc44hSXO|YYm= MonCOUDPxE1? NI\1dok1QC95MjDo MVzEUXNQ NYqyOlZLe3WycILld5NmeyCneIDy[ZN{cW:wIH;mJJRp\SCFWFPSOEBidmRiTV3QNVQheHKxdHXpci=> MXmyOFM6QTB5NB?=
HMEpC MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrMPZc4OSCwTT2xNFAh|ryP MYq0POKhcMLi MUjEUXNQ NWL4bW1ncW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NHHEZpMzPDF|OEi0Ny=>
MCF-7 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFX1WYQyKG6PLUGwNEDPxE1? M3vYVVQ5yqCqwrC= MVHEUXNQ MXnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MkC0NlQyOzh6NEO=
ZR-75-1 M2\yUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzQZYIyOSCwTT2xNFAh|ryP MX[0POKhcMLi MUnEUXNQ M4nUT4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M2juXVI1OTN6OESz
MDA-MB-231 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\rNUBvVS1zMECg{txO MV20POKhcMLi NIHKPVVFVVOR M{TGe4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MVqyOFE{QDh2Mx?=
MDA-MB-468 M1XJemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:1bJEzOSCwTT2xNFAh|ryP NGnVeIM1QMLiaNMg NEfRVXhFVVOR NWLvOodScW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MlLKNlQyOzh6NEO=
T-47-D MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTKNUBvVS1zMECg{txO Mnm5OFjDqGkEoB?= M{T5ZmROW09? NEX1NWJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? Mlq1NlQyOzh6NEO=
U251  MVvGeY5kfGmxbjDBd5NigQ>? MnvWNk81NzkkgJpOwQKFu8Li MWC2M|EzNzJ2IHi= NHXYXJBFVVOR NXq4OnR4cW6lcnXhd4V{KHSqZTDMR|MuUUlibHX2[YwhcW5iYTD0bY1mNWSncHXu[IVvfCCjbnSg[I9{\S2mZYDlcoRmdnRibXHucoVz MWWyN|c6QTh3Mh?=
U87MG NGDN[5NHfW6ldHnvckBCe3OjeR?= Mme0Nk81NzkkgJpOwQKFu8Li M1XiSlYwOTJxMkSgbC=> NVvZU|U{TE2VTx?= MW\pcoNz\WG|ZYOgeIhmKEyFMz3JTUBt\X[nbDDpckBiKHSrbXWt[IVx\W6mZX70JIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NUX4R2RlOjN5OUm4OVI>
U251  M{Hq[mZ2dmO2aX;uJGF{e2G7 MXe05qCK|r{khMRCpC=> MVeyM|YwOTJiaB?= NHntS|FFVVOR NVe0bYxie3WycILld5NmeyCkYYPhcEBt\X[nbIOgc4YheGixc4Doc5J6dGG2aX;uJI9nKFN4IDjTNlM2NzJ|NjmsJFRGNUKSMTCoWFM4NzR4KTygZY5lKEGtdDCoV|Q4OyliaX6gZUB1cW2nLXTldIVv\GWwdDDtZY5v\XMEoB?= NH74T|AzOzd7OUi1Ni=>
U87MG MU\GeY5kfGmxbjDBd5NigQ>? MVO05qCK|r{khMRCpC=> MYqyM|YwOTJiaB?= MljDSG1UVw>? MUjzeZBxemW|c3XzJIJie2GuIHzleoVteyCxZjDwbI9{eGixconsZZRqd25ib3[gV|YhMFN{M{WvNlM3MSxiNFWtRnAyKCiWM{evOFYqNCCjbnSgRYt1KCiVNEezLUBqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7lduKh NXXVd5dYOjN5OUm4OVI>
H1650  MmPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jMNGlEPTB;Mz61xtEyNjJizszN MYeyN|I4PDd3OB?=
HUVECs  NGC2WodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\xRnhvPzJiaB?= NUjhUpRYUUN3MNMgQUA4NjFizsztc4wwVA>? NWLvVmtCOjJ4MUGwNlc>
KYN-2  MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVi3NkBp MYfJR|UxyqB;IEiuNUDPxG2xbD;M NYja[2pTOjJ4MUGwNlc>
HuH-7  M2j6WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYL3e5FSPzJiaB?= MV\JR|UxyqB;IEmuOEDPxG2xbD;M Mo\KNlI3OTFyMke=
HUVECs  M3PSUmZ2dmO2aX;uJGF{e2G7 M13KSlEwPS9zMDFOwG0> MnrDNUBp MXjzbYdvcW[rY3HueIx6KGmwaHnibZR{KF[HR1\SMVIheGixc4Doc5J6dGG2aX;u NUK5[HU3OjJ4MUGwNlc>
HAK1-B MWDGeY5kfGmxbjDBd5NigQ>? NYjPOZJxOS93L{GwJO69VQ>? NVf4NIU4OSCq NFrwfnp{fXCycnXzd4V{KEWJRmKgdIhwe3Cqb4L5cIF1cW:w NIf5[5ozOjZzMUCyOy=>
UM-22A NH;seWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYewMVYh|ryP M3TJOlczKGh? MnPOSG1UVw>? Mk\IbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M{K0bFIzOzB5N{O1
UM-22B Mlz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;5XY8xNTZizszN M4r3SFczKGh? MlPkSG1UVw>? M2frfIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M1nUPVIzOzB5N{O1
PCI-37A NUnWXZhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXThZZV{OC14IN88US=> NHzQT|Y4OiCq MnztSG1UVw>? M3fERYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MWqyNlMxPzd|NR?=
PCI-37B NGP2UXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2r3VlAuPiEQvF2= NGjMPJM4OiCq NGHCbmNFVVOR M1z3UIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NF74ToUzOjNyN{ezOS=>
PCI-15B M13lZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nJ[VAuPiEQvF2= Mk\IO|IhcA>? MlzFSG1UVw>? MkLybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MlSyNlI{ODd5M{W=
SCC-25 NUW4RVVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17De|AuPiEQvF2= NVTIXG45PzJiaB?= NWj2blNlTE2VTx?= Mo\RbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MkX1NlI{ODd5M{W=
UM-22A NYLrT5A5TnWwY4Tpc44hSXO|YYm= NEjYdpMxNTFyIN88US=> MoSyNlQhcA>? NH3ZSVFFVVOR NGnQeWVqdmirYnn0d{B1cGViYXP0bZZifGmxbjDv[kB1cGViRVfGVkB1gXKxc3nu[UBscW6jc3WgZY5lKGGuc3:g[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJBpd3OyaH;yfYxifGWmIH\vdo1{KG:oIITo[UBld3ewc4Ty[YFuKHOrZ37hcIlv\yCnbHXt[Y51eyxiU2TBWFMh[W6mIF3BVGs> NX23VYVLOjJ|MEe3N|U>
UM-22B M{j0fGZ2dmO2aX;uJGF{e2G7 NF62W24xNTFyIN88US=> MXmyOEBp M4nNc2ROW09? M1exUIlvcGmkaYTzJJRp\SCjY4TpeoF1cW:wIH;mJJRp\SCHR1\SJJR6em:|aX7lJItqdmG|ZTDhcoQh[Wy|bzDk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gdIhwe3Cqb4L5cIF1\WRiZn;ycZMhd2ZidHjlJIRwf26|dILlZY0he2mpbnHsbY5oKGWuZX3lcpR{NCCVVFHUN{BidmRiTVHQTy=> NF\TbIgzOjNyN{ezOS=>
PCI-15B MlzwSpVv[3Srb36gRZN{[Xl? MoHCNE0yOCEQvF2= NUfB[5JHOjRiaB?= NX65TZhjTE2VTx?= MXXpcohq[mm2czD0bIUh[WO2aY\heIlwdiCxZjD0bIUhTUeIUjD0fZJwe2mwZTDrbY5ie2ViYX7kJIFte29iZHXjdoVie2W|IITo[UBmgHC{ZYPzbY9vKG:oIIDoc5NxcG:{eXzheIVlKG[xcn3zJI9nKHSqZTDkc5dve3S{ZXHtJJNq\26jbHnu[{BmdGWvZX70d{whW1SDVEOgZY5lKE2DUFu= M3XEW|IzOzB5N{O1
PCI-37A M1LENWZ2dmO2aX;uJGF{e2G7 NUTXd5pjOSEQvF2= NVfw[VFIOjRiaB?= M4qxN2ROW09? NUfOfGZp\G:5boLl[5Vt[XSnczDWSWdHKHC{b3T1Z5Rqd25? NIHCUFQzOjNyN{ezOS=>
UM-22A M3Gxe2Z2dmO2aX;uJGF{e2G7 NUHDOGpzOSEQvF2= Moj4NlQhcA>? Ml\CSG1UVw>? NEjDe4lld3ewcnXneYxifGW|IG\FS2YheHKxZIXjeIlwdg>? MXGyNlMxPzd|NR?=
PCI-15B NVPJVnRRTnWwY4Tpc44hSXO|YYm= NWDOdZhPOSEQvF2= NXz1c4pMOjRiaB?= MW\EUXNQ MUTkc5dvemWpdXzheIV{KF[HR1[gdJJw\HWldHnvci=> MnnqNlI{ODd5M{W=
PCI-15B MU\JcpZie2mxbjDBd5NigQ>? MnfLNlQhcA>? M1f6[WROW09? Mn;RSWM2OD13NUigcm0> NE\kU20zOjNyN{ezOS=>
PCI-37A NILRPI9Kdn[jc3nvckBCe3OjeR?= MlPDNlQhcA>? NHn6[HVFVVOR NGPs[nFGSzVyPUG2PVUhdk1? MUeyNlMxPzd|NR?=
UM-22A MWTJcpZie2mxbjDBd5NigQ>? Mk\aNlQhcA>? MVTEUXNQ MYLFR|UxRTBwMzDuUS=> MnXONlI{ODd5M{W=
SCC-25 NELKfGNKdn[jc3nvckBCe3OjeR?= NHrRSYszPCCq MV\EUXNQ MYjFR|UxRTFyIH7N M4HlPFIzOzB5N{O1
UM-22B NV3BOIc6UW64YYPpc44hSXO|YYm= M1LaZVI1KGh? M1;lWmROW09? NHWz[JJGSzVyPUK0NlQhdk1? M3rPTlIzOzB5N{O1
PCI-37B Mnu1TY53[XOrb36gRZN{[Xl? NWTxSmM4OjRiaB?= M3jrc2ROW09? Mni2SWM2OD1zN{K2JI5O NWPnT3lrOjJ|MEe3N|U>
201T NVn3cXBFTnWwY4Tpc44hSXO|YYm= M1vRVVIvPSEQvF2= NWC5T|JJPDhiaB?= M3PFT2ROW09? NFOwXJVqdmirYnn0d{BxcG:|cHjvMW1CWEtiZn;scI94cW6pIFXHSi=> MXiyNlI2QDR5Nh?=
273T  MUHGeY5kfGmxbjDBd5NigQ>? M3zGU|IvPSEQvF2= NWrkN4FGPDhiaB?= M13NO2ROW09? NXPlSIl3cW6qaXLpeJMheGixc4Doc{1OSVCNIH\vcIxwf2mwZzDFS2Y> MX[yNlI2QDR5Nh?=
A549 M1HreGZ2dmO2aX;uJGF{e2G7 M372RVIvPSEQvF2= NEHrOYM1QCCq M1H4WWROW09? MXnpcohq[mm2czDwbI9{eGixLV3BVGsh\m:ubH;3bY5oKEWJRh?= M1e0U|IzOjV6NEe2
201T  MXTGeY5kfGmxbjDBd5NigQ>? MYqxM|UwOTBizszN MVu0PEBp M{PlXmROW09? MkfFZoxw[2u|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhSWu2IHnu[JVk\WRiYomgWmVITkN? MoLqNlIzPTh2N{[=
H2052 NXHSZYg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVeyUHVQUUN3ME2xMlA4yrFyLkC0JO69VQ>? MVqyNVk4ODh5NB?=
H2452 M2\jd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPCOGVsUUN3ME2zMlUzyrFzLkGzJO69VQ>? MUiyNVk4ODh5NB?=
H28 M2PLNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fPWmlEPTB;MD6zNuKyOC5yNzFOwG0> NGnPW5IzOTl5MEi3OC=>
MSTO-211H NEfodFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjJOVNKSzVyPUGuOFLDuTBwMEOg{txO MVeyNVk4ODh5NB?=
Hth83 M1S1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfIO|IhcA>? NH:4VFBFVVOR MXnJR|UxRTNwM{CgxtEhOC54NjFOwG0> M{fyXVIyOjJyNEe3
C643 NF3NPGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTlO|IhcA>? NWTEOFNbTE2VTx?= MVzJR|UxRTNwNkWgxtEhOS5{MjFOwG0> MWCyNVIzODR5Nx?=
8505C NH\rcnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1f0S|czKGh? MkTxSG1UVw>? NGrN[VVKSzVyPUeuOVYhyrFiMT6xN{DPxE1? NUXTepNPOjF{MkC0O|c>
Hth74 Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWO3NkBp M3jwXGROW09? MWnJR|UxRThwNU[gxtEhOS5yMTFOwG0> MnXHNlEzOjB2N{e=
SW1736 MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW[3NkBp MmHuSG1UVw>? M3nh[GlEPTB;OT6wOUDDuSByLkW1JO69VQ>? NWWwR4pEOjF{MkC0O|c>
Hth7 M4j6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVK3NkBp Ml3oSG1UVw>? M3rDcWlEPTB;OT62OkDDuSByLkO4JO69VQ>? MWmyNVIzODR5Nx?=
Hth104 M{K5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLMW2xvPzJiaB?= NHrBOolFVVOR NELnXIpKSzVyPdMxNVYvQThiwsGgUmEh|ryP MUGyNVIzODR5Nx?=
HTB3 NVjzTWx[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M122VlAuOjBizszN NIjldm0zPMLiaB?= M2\Yc4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M2HzXFE6OjJyMkW2
HT1376 M1nXS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LlcFAuOjBizszN M1TNfFI1yqCq MVzpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NVfVOI1iOTl{MkCyOVY>
RT4 Mlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVntNIZXOC1{MDFOwG0> NHS4UGEzPMLiaB?= MVTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MWCxPVIzODJ3Nh?=
J82 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUCwMVIxKM7:TR?= M3LMRlI1yqCq M{D2Z4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NYjaT|ZzOTl{MkCyOVY>
CRL1749 M2DWOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PocFAuOjBizszN MV2yOOKhcA>? M{fGRolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M2PXUVE6OjJyMkW2
T24 NIXwd2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLRUoRXOC1{MDFOwG0> MVSyOOKhcA>? NGXpNVdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NXT0WG5xOTl{MkCyOVY>
SUP NYTJepBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIriVXgxNTJyIN88US=> NY\HXmdLOjUEoHi= MXfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NGO4RlkyQTJ{MEK1Oi=>
HTB9 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLvR4MxNTJyIN88US=> MWmyOOKhcA>? NVXudVRvcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NGn3NoIyQTJ{MEK1Oi=>
ACC3 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTieGR6OC1zMDFOwG0> NFLNRVY4OiCq MoTsbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M4r2UVE5Pjl6MEK1
ACC2 NIrFSGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnT4NE0yOCEQvF2= M1LmT|czKGh? M4rK[4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz Mk[yNVg3QThyMkW=
ACCM NGDC[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHZfJgxNTFyIN88US=> NHnEZZA4OiCq NXj6c4t2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M{nQTFE5Pjl6MEK1
ACC3 NHrORnZCeG:ydH;zbZNqKEG|c3H5 MVKwMVExKM7:TR?= NE\RbZM4OiCq M1;OZ4lv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm= NUP2fnExOTh4OUiwNlU>
ACC2 M1r3OmFxd3C2b4Ppd4khSXO|YYm= NFXoTIcxNTFyIN88US=> M1TZUlczKGh? MYLpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 MWGxPFY6QDB{NR?=
ACCM NXnNW21FSXCxcITvd4l{cSCDc4PhfS=> MlO5NE0yOCEQvF2= M{XU[lczKGh? NIfISoxqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 MXexPFY6QDB{NR?=
EHMES-1 M1r1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDtTpA4OiCq MUHEUXNQ NUjrSHd7UUN3ME2xNE43KM7:TR?= MUixPFM3PDJ2OB?=
EHMES-10 NUnINGd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIi2PXc4OiCq NYC5bIRvTE2VTx?= NWq5enYyUUN3ME2wMlMh|ryP MlTINVg{PjR{NEi=
211H MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV63NkBp MnzuSG1UVw>? NHPCdHVKSzVyPUKuNkDPxE1? M{fEb|E5OzZ2MkS4
H28 M2PlPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3POUlczKGh? M4q5O2ROW09? MVPJR|UxRTFwODFOwG0> NE\xfZMyQDN4NEK0PC=>
H2052 NHLtNHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXZSFQ4OiCq NGfReYxFVVOR M{WxNWlEPTB;OD6wJO69VQ>? MUSxPFM3PDJ2OB?=
H2452 MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHGxbow4OiCq M4HNb2ROW09? NF;lPWdKSzVyPUWuOUDPxE1? MlXRNVg{PjR{NEi=
CNE-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTQcXZGOC5zLUK1MlYh|ryP NYDiPVF6PDhiaB?= NFf1b5RKSzVyPUOuOkDPxE1? MmjONVc3OzF4NE[=
CNE-2 NYXIblA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnsNE4yNTJ3Lk[g{txO NULuW|dZPDhiaB?= NWnOfJZWUUN3ME22MlIh|ryP NHHGVXcyPzZ|MU[0Oi=>
C666-1 M4\HO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPpcYoxNjFvMkWuOkDPxE1? NUXhTXVpPDhiaB?= NITrWItKSzVyPUKzMlQh|ryP MXqxO|Y{OTZ2Nh?=
CNE-1 Ml21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPNNE4yNTJ3Lk[g{txO NIO3TVE4OiCq Mn;RTWM2OD1{LkOg{txO M3fiV|E4PjNzNkS2
CNE-2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\RUY8xNjFvMkWuOkDPxE1? NGPZSIU4OiCq M4LFVmlEPTB;Mz62JO69VQ>? NGfE[YcyPzZ|MU[0Oi=>
C666-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4m1NlAvOS1{NT62JO69VQ>? M2\KS|czKGh? M{LCV2lEPTB;ND64OkDPxE1? NUHPUlR2OTd4M{G2OFY>
CNE-1 Ml7ISpVv[3Srb36gRZN{[Xl? MlfTOkDPxE1? NUPrcWZzOjRiaB?= MV3k[YxigXNiR{CvS|Eh[2WubDDjfYNt\SCycn;ndoV{e2mxbh?= MVOxO|Y{OTZ2Nh?=
CNE-2 M1;pT2Z2dmO2aX;uJGF{e2G7 NWfqcXhKPiEQvF2= MUmyOEBp MWLk[YxigXNiR{CvS|Eh[2WubDDjfYNt\SCycn;ndoV{e2mxbh?= NF\5TIwyPzZ|MU[0Oi=>
C666-1 NUnWZ41RTnWwY4Tpc44hSXO|YYm= NEC4Tms3KM7:TR?= MmnuNlQhcA>? NV3rVZQ2\GWuYYnzJGcxN0dzIHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44> NEnRRlAyPzZ|MU[0Oi=>

... Click to View More Cell Line Experimental Data

In vivo Vandetanib (2.5 mg/kg, i.v.), reverses a VEGF-induced hypotension by 63% but does not significantly affect a bFGF-induced hypotension. Vandetanib (100 mg/kg) inhibits the tumor-induced blood vessel formation by 79%. Vandetanib (12.5-100 mg/kg, orally) shows great tumor growth inhibition in human tumor xenografts including Calu-6, PC-3, MDA-MA-231, SKOV-3, SW620, A549, A431, B16-F10(AP3) and Lewis Lung, with little effects on body weight. [1] In PC3wt xenografts, administration of Vandetanib alone exerts paradoxical tumor growth stimulating effects. In PC3R xenografts, the low dose of Vandetanib (25 mg/kg) has no significant effect relative to control, whereas the high dose (50 mg/kg) significantly inhibits tumor growth compared with control. In contrast, the high-dose combination reveals a significant negative interaction between Vandetanib 50 mg/kg and docetaxel 30 mg/kg in PC3R cells. [3] In tumor-bearing mice, Vandetanib suppresses phosphorylation of VEGFR2 and EGFR in tumor tissues, significantly decreases tumor vessel density, enhances tumor cell apoptosis, suppresses tumor growth, improves survival, reduces number of intrahepatic metastases, and up-regulates VEGF, TGF-alpha and EGF in tumor tissues. Treatment with Vandetanib is not associated with serious adverse events, including ALT abnormality, bone marrow suppression or body weight loss. [4] Vandetanib treatment of nude mice bearing palpable GEO colon cancer xenografts (which are sensitive to inhibition of EGFR signaling) induces dose-dependent tumor growth inhibition. [5]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase inhibition:

Vandetanib is incubated with enzyme, 10 mM MnCl2, and 2 μM ATP in 96-well plates coated with a poly(Glu, Ala, Tyr) 6:3:1 random copolymer substrate. Phosphorylated tyrosine is then detected by sequential incubation with a mouse IgG anti-phosphotyrosine 4G10 antibody, a horseradish peroxidase-linked sheep antimouse immunoglobulin antibody, and 2,2′-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid). This methodology is adapted to examine selectivity versus tyrosine kinases associated with EGFR, PDGFRβ, Tie-2, FGFR1, c-kit, erbB2, IGF-1R, and FAK. All enzyme assays (tyrosine or serine-threonine) used appropriate ATP concentrations at or just below the respective Km (0.2–14 μM). Selectivity versus serine-threonine kinases (CDK2, AKT, and PDK1) is examined using a relevant scintillation proximity-assay (SPA) in 96-well plates. CDK2 assays contained 10 mM MnCl2, 4.5 μM ATP, 0.15 μCi of [γ-33 P]ATP/reaction, 50 mM HEPES (pH 7.5), 1 mM DTT, 0.1 mM sodium orthovanadate, 0.1 mM sodium fluoride, 10 mM sodium glycerophosphate, 1 mg/mL BSA fraction V, and a retinoblastoma substrate (part of the retinoblastoma gene, 792–928, expressed in a glutathione S-transferase expression system; 0.22 μM final concentration). Reactions are allowed to proceed at room temperature for 60 minutes before quenching for 2 hours with 150 μL of a solution containing EDTA (62 mM final concentration), 3 μg of a rabbit immunoglobulin anti-glutathione S-transferase antibody and protein A SPA-polyvinyltoluene beads (0.8 mg/reaction). Plates are then sealed, centrifuged (1200× g for 5 minutes), and counted on a Microplate scintillation counter for 30 seconds.
Cell Research:

[1]

+ Expand
  • Cell lines: Calu-6, PC-3, MDA-MA-231, SKOV-3, SW620, A549, A431, B16-F10(AP3) and Lewis Lung cells
  • Concentrations: 0.1–100 μM
  • Incubation Time: 72 hours
  • Method:

    Tumor cells are plated in their respective media at predetermined densities that are known to enable logarithmic cell growth during the period of assay (PC-3, 500 cells/well; all others, 1000 cells/well). Plates are incubated for 24 hours (37 °C with CO2) before the addition of Vandetanib (0.1–100 μM) or vehicle (0.1% DMSO in medium). Plates are reincubated for an additional 72 hours before assessing cell proliferation by [3 H]thymidine incorporation by a beta counter.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: Female athymic (nu/nu genotype) Swiss mice with PC-3, Calu-6, SKOV-3, and MDA-MB-231 tumors
  • Formulation: 1% (v/v) solution of polyoxyethylene
  • Dosages: 12.5 mg/kg/day, 25 mg/kg/day, 50 mg/kg/day, or 100 mg/kg/day
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (8.41 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% CMC Na
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 475.35
Formula

C22H24BrFN4O2

CAS No. 443913-73-3
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03630120 Recruiting Thyroid Cancer|Thyroid Cancer Medullary|Differentiated Thyroid Cancer|Papillary Thyroid Cancer|Follicular Thyroid Cancer|Poorly Differentiated Thyroid Gland Carcinoma H. Lee Moffitt Cancer Center and Research Institute August 6 2018 Phase 2
NCT03291379 Recruiting Carcinoma Hepatocellular|Metastatic Colorectal Cancer Biocompatibles UK Ltd May 17 2017 Early Phase 1
NCT02638428 Recruiting Relapsed Pediatric Solid Tumor|Refractory Pediatric Solid Tumor|Relapsed Pediatric AML|Refractory Pediatric AML Samsung Medical Center|Ministry of Health Republic of Korea December 2015 Phase 2
NCT02495103 Recruiting Renal Cell Carcinoma|Hereditary Leiomyomatosis and Renal Cell Cancer|Papillary Renal Cell Carcinoma Sporadic National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 8 2015 Phase 1|Phase 2
NCT02530411 Recruiting Neoplasms Velindre NHS Trust|Cancer Research UK|AstraZeneca April 2015 Phase 2
NCT02239952 Recruiting Cancer|High-grade Glioma VU University Medical Center November 2014 Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products4

Tags: buy Vandetanib (ZD6474) | Vandetanib (ZD6474) supplier | purchase Vandetanib (ZD6474) | Vandetanib (ZD6474) cost | Vandetanib (ZD6474) manufacturer | order Vandetanib (ZD6474) | Vandetanib (ZD6474) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID